Begin main content

Sofosbuvir for the Treatment of Patients with Genotype 4 Hepatitis C: A Review of the Clinical Efficacy, Cost-effectiveness, and Guidelines

Published on: December 5, 2014
Project Number: RC0612-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the clinical efficacy of sofosbuvir for the treatment of adults with genotype 4 chronic hepatitis C?
  2. What is the cost-effectiveness of sofosbuvir for the treatment of adults with genotype 4 chronic hepatitis C?
  3. What are the evidence-based guidelines for the treatment of adults with genotype 4 chronic hepatitis C?

Key Message

Sofosbuvir in combination with peginterferon and ribavirin is recommended for treatment of naïve-patients, who are eligible and not eligible to receive interferon, as well as those who are peginterferon/ribavirin non-responders. There was no evidence of comparative clinical efficacy and cost-effectiveness of sofosbuvir for the treatment of HCV genotype 4 identified.

Tags

genotype, hepacivirus, hepatitis c, infectious diseases, sofosbuvir, Sovaldi, Chronic